Theoretical implications of the use of L-dopa in parkinsonism. A review.
D000109:Acetylcholine / Q000378:metabolism; D000547:Amantadine / Q000627:therapeutic use; D000818:Animals; D002415:Cats; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004298:Dopamine / Q000096:biosynthesis; D005260:Female; D000882:Haplorhini; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D009069:Movement Disorders / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology; D012701:Serotonin / Q000502:physiology; D013378:Substantia Nigra / Q000473:pathology; D009435:Synaptic Transmission
D012701:Serotonin; D004295:Dihydroxyphenylalanine; D000547:Amantadine; D000109:Acetylcholine; D004298:Dopamine